AJP - Heart Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 289: H2039-H2047, 2005. First published July 1, 2005; doi:10.1152/ajpheart.00479.2005
0363-6135/05 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
289/5/H2039    most recent
00479.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (26)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Booth, E. A.
Right arrow Articles by Lucchesi, B. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Booth, E. A.
Right arrow Articles by Lucchesi, B. R.

Activation of estrogen receptor-{alpha} protects the in vivo rabbit heart from ischemia-reperfusion injury

Erin A. Booth, Nabeel R. Obeid, and Benedict R. Lucchesi

Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan

Submitted 10 May 2005 ; accepted in final form 24 June 2005

The estrogen receptor (ER) mediates estrogenic activity in a variety of organs, including those in the reproductive, cardiovascular, immune, and central nervous systems. Experimental studies have demonstrated that 17{beta}-estradiol (E2) protects the heart from ischemia-reperfusion injury. Two estrogen receptors, ER{alpha} and ER{beta}, mediate the actions of estrogen; however, it is not certain which ER mediates the cardioprotective effects of E2. In the present study, the ER-selective agonists 4,4',4''-[4-propyl-(1H)-pyrazole-1,3,5-triyl]tris-phenol (PPT; ER{alpha}) and 2,3-bis(4-hydroxyphenyl)-propionitrile (DPN; ER{beta}) were assessed for their cardioprotective potential in an in vivo rabbit model of ischemia-reperfusion injury. Anesthetized female rabbits were administered PPT (3 mg/kg), DPN (3 mg/kg), E2 (20 µg/rabbit), or vehicle intravenously 30 min before a 30-min occlusion of the left anterior descending coronary artery followed by 4 h of reperfusion. Acute treatment with E2 (17.7 ± 2.9%; P < 0.001) and PPT (18.1 ± 2.9%; P < 0.001), but not DPN (45.3 ± 2.4%) significantly decreased infarct size as a percent of area at risk compared with vehicle (45.3 ± 2.4%). Coadministration of PPT or E2 with the ER antagonist ICI-182,780 limited the infarct size-sparing effect of the compounds (43.8 ± 6.6% and 40.6 ± 5.7% respectively, expressed as a percentage of risk region). PPT reduced the release of cardiac-specific troponin-I and reduced the tissue deposition of the membrane attack complex and C-reactive protein similar to that of E2. The results indicate that activation of ER{alpha}, but not ER{beta}, is required for the observed cardioprotective effects of E2.

infarct size; membrane attack complex; C-reactive protein; estrogen; 4,4&",4&"-[4-propyl-(1H)-pyrazole-1,3,5-triyl]tris-phenol



Address for reprint requests and other correspondence: B. R. Lucchesi, Dept. of Pharmacology, Univ. of Michigan Medical School, 1301C Medical Science Research Bldg. III, Ann Arbor, MI 48109-0632 (e-mail: benluc{at}umich.edu)




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. J. Merkel, L. Liu, Z. Cao, W. Packwood, P. D. Hurn, and D. M. Van Winkle
Estradiol abolishes reduction in cell death by the opioid agonist Met5-enkephalin after oxygen glucose deprivation in isolated cardiomyocytes from both sexes
Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H409 - H415.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
E. A. Booth and B. R. Lucchesi
Medroxyprogesterone acetate prevents the cardioprotective and anti-inflammatory effects of 17beta-estradiol in an in vivo model of myocardial ischemia and reperfusion
Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1408 - H1415.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
E. Murphy and C. Steenbergen
Gender-based differences in mechanisms of protection in myocardial ischemia-reperfusion injury
Cardiovasc Res, August 1, 2007; 75(3): 478 - 486.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
C. Bolego, E. Vegeto, C. Pinna, A. Maggi, and A. Cignarella
Selective Agonists of Estrogen Receptor Isoforms: New Perspectives for Cardiovascular Disease
Arterioscler. Thromb. Vasc. Biol., October 1, 2006; 26(10): 2192 - 2199.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. Wang, P. Crisostomo, G. M. Wairiuko, and D. R. Meldrum
Estrogen receptor-{alpha} mediates acute myocardial protection in females
Am J Physiol Heart Circ Physiol, June 1, 2006; 290(6): H2204 - H2209.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
F. Di Lisa
A Female Way to Protect the Heart: Say NO to Calcium
Circ. Res., February 17, 2006; 98(3): 298 - 300.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2005 by the American Physiological Society.